Article
Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer.
Neoplasia (New York, N.Y.) - 1 Dec 2025
Ahmad Fahim, White Margaret, Yamamoto Kazutoshi, Crooks Daniel R, Agarwal Supreet, Yang Ye, Capaldo Brian, Raj Sonam, Alilin Aian Neil, Ton Anita, Adler Stephen, Seidel Jurgen, Olkowski Colleen, Cherukuri Murali Krishna, Choyke Peter L, Kelly Kathleen, Brender Jeffrey R
Abstract excerpt
Advanced prostate cancer is treated with androgen receptor (AR) signaling inhibitors, which are initially effective, but most patients eventually develop resistance and progress to castrate-resistant prostate cancer (CRPC). Loss of RB1 in CRPC tumors is correlated with rapid progression and poor patient survival and, in combination with TP53 loss, predisposes patients to the development of transitional...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.